GeoVax Labs Inc (GOVX)

[3DYOGI]

HIV - Immunotherapy Program
HIV - Preventive Vaccine
Hemorrhagic Fever Vaccine
Our Hepatitis B Therapeutic Vaccine Program
Our Malaria Vaccine Program
Our Zika Virus Vaccine Program

http://www.foxnews.com/health/2016/02/10/scientists-attack-zika-virus-from-multiple-angles.html
If a pandemic was to happen with Zika GOVX could develop the vaccine within 2 years.

Our Cancer Immunotherapy Program
About Cancer Immunotherapy. Cancer is the second most common cause of death in the US, exceeded only by heart disease. Its global burden is expected to rise to 22 million new cases by 2030. Currently, there is only one FDA approved cancer vaccine, PROVENGE® (sipuleucel-T) a personalized therapy for prostate cancer patients. However, the field of immune-oncology has received new momentum with the discovery and initial launch of monoclonal antibodies (Mabs) called immune checkpoint inhibitors (ICIs). Tumors hijack the body’s natural immune checkpoints by over expressing immune checkpoint ligands (proteins that bind to and activate the inhibitory activity of immune checkpoints), as a mechanism of immune resistance, especially against the T cells that are specific for tumor antigens and can kill cancer cells. ICIs block the interaction of Immune checkpoints with their ligands on tumor cells, allowing poorly functional T cells to resume proliferation, cytokine production and killing of tumor cells.

Unlike conventional therapies (e.g. radiation, chemotherapy, antibody, etc.), cancer vaccines have the potential to induce responses that not only result in the control and even clearance of tumors but also establish immunological memory that can suppress and prevent tumor recurrence. Convenience, safety, and low toxicity of cancer vaccines make them invaluable tools to be included in future immunotherapy approaches for treating tumors. Currently, there are only a few vectored cancer vaccines being tested in combination with ICIs, all of which are in early clinical stages.

Our Immuno-Oncology Development Efforts. GeoVax has established a collaboration with Dr. Olivera Finn, a leading expert in cancer immunotherapy at the University of Pittsburgh. She was the first to show that many tumors express an abnormal form of cell surface-associated Mucin 1 (MUC1) protein could be recognized by the immune system as foreign. Given this, we are using our MVA-VLP vaccine platform to deliver abnormal forms of MUC1 (e.g. hypo-glycosylated forms found in tumors) (Figure 1) with the goal of raising protective anti-tumor antibodies and T cell responses in cancer patients.

https://www.geovax.com/technologypipeline.html


http://starlocalmedia.com/theleader/news/first-case-of-zika-virus-confirmed-in-denton-county/article_9f461c04-10e7-11e7-bf76-1bf78a99764d.html
First case of Zika virus confirmed in Denton County

$GOVX